BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AMT-116 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of AMT-116\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05725291-2088@assetmemo.bio
DTSTAMP:20261121T005909Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:AMT-116: Phase 1 readout est. (NCT05725291)
DESCRIPTION:AMT-116\, phase 1.\nStudy: AMT-116 in Patients With Advanced So
 lid Tumors\nEstimated primary completion: 30 December 2026. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/amt-116#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05725291
URL:https://assetmemo.bio/drug/amt-116#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07590531-2088@assetmemo.bio
DTSTAMP:20261121T005909Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:AMT-116: Phase 1/2 readout est. (NCT07590531)
DESCRIPTION:AMT-116\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: AMT-1
 16 in Combination With AK112 in Patients With Lung Cancer\nEstimated prima
 ry completion: 30 May 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/amt-116#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07590531
URL:https://assetmemo.bio/drug/amt-116#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07718737-2088@assetmemo.bio
DTSTAMP:20261121T005909Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:AMT-116: Phase 2/3 readout est. (NCT07718737)
DESCRIPTION:AMT-116\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: Globa
 l\, Multicenter Study of AMT-116 Versus Investigator's Choice in Participa
 nts With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell 
 Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemothera
 py and Anti-PD-1/PD-L1 Immunotherapy\nEstimated primary completion: 30 Mar
 ch 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/amt-116#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07718737
URL:https://assetmemo.bio/drug/amt-116#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
